| __timestamp | Genmab A/S | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79529000 | 15746000 |
| Thursday, January 1, 2015 | 91224000 | 13392000 |
| Friday, January 1, 2016 | 102413000 | 9290000 |
| Sunday, January 1, 2017 | 146987000 | 7672000 |
| Monday, January 1, 2018 | 213695000 | 15293000 |
| Tuesday, January 1, 2019 | 342000000 | 22648000 |
| Wednesday, January 1, 2020 | 661000000 | 21864000 |
| Friday, January 1, 2021 | 1283000000 | 37318000 |
| Saturday, January 1, 2022 | 2676000000 | 48130000 |
| Sunday, January 1, 2023 | 3297000000 | 108146000 |
| Monday, January 1, 2024 | 3790000000 |
Igniting the spark of knowledge
In the competitive world of pharmaceuticals, understanding the financial strategies of leading companies is crucial. This chart provides a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of Genmab A/S and Madrigal Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Genmab A/S has seen a staggering increase in SG&A expenses, growing by over 4,000%, from approximately $80 million in 2014 to nearly $3.3 billion in 2023. This reflects Genmab's aggressive expansion and investment in its operations.
In contrast, Madrigal Pharmaceuticals, Inc. has maintained a more conservative growth trajectory, with SG&A expenses increasing by around 600% over the same period. This difference highlights the varied strategic approaches within the industry, with Genmab focusing on rapid growth and Madrigal opting for steady development. Such insights are invaluable for investors and industry analysts alike.
Zoetis Inc. and Genmab A/S: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: argenx SE vs Madrigal Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Genmab A/S and Axsome Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Genmab A/S or Cytokinetics, Incorporated
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Madrigal Pharmaceuticals, Inc. and ImmunityBio, Inc.
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or MannKind Corporation
Operational Costs Compared: SG&A Analysis of Madrigal Pharmaceuticals, Inc. and Xencor, Inc.